Physician profile
Barry Schechter
NPI 1487716494
$264,007.88
in general payments reported to CMS, 2019-2025
32 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $16K · 2021: $19K · 2022: $45K · 2023: $43K · 2024: $25K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $70K · Honoraria: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $12K · Travel and Lodging: $9,500 · Consulting Fee: $5,914 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $70,492.50 |
| Honoraria | $28,262.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,740.00 |
| Food and Beverage | $11,996.21 |
| Travel and Lodging | $9,500.07 |
| Consulting Fee | $5,913.50 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $92,725.02 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $74,520.59 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31,876.28 | 2019-2021 | |
| Horizon Therapeutics Plc | $20,014.15 | 2021-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $15,019.07 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $12,568.96 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $4,333.98 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $3,490.85 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| New World Medical,INC. | $2,377.11 | 2021-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Harrow Eye, LLC | $1,714.48 | 2024-2025 | Vevye, Iheezo |
| Abbvie INC. | $1,057.33 | 2022-2025 | Durysta |
| Tarsus Pharmaceuticals, INC. | $641.23 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $571.05 | 2019-2025 | Oxervate |
| Glaukos Corporation | $542.03 | 2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $421.01 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $298.25 | 2019-2025 | Simbrinza, Rocklatan |
| Dr.Reddy'S Laboratories,INC. | $276.00 | 2025 | |
| Ocular Therapeutix, INC. | $236.15 | 2021-2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $198.78 | 2019-2021 | |
| Rxsight INC | $197.99 | 2021-2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $179.25 | 2019-2021 | |
| Shire North American Group INC | $167.23 | 2019 | |
| Ivantis, INC | $136.73 | 2019-2021 | |
| Oyster Point Pharma, INC. | $109.25 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $62.97 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $58.16 | 2024-2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $54.02 | 2023-2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| Regeneron Healthcare Solutions, INC. | $53.89 | 2021-2023 | Eylea |
| Biotissue Holdings INC. | $34.36 | 2022 | |
| Sight Sciences, INC. | $34.19 | 2021 | |
| Neurotech Pharmaceuticals, INC. | $20.42 | 2025 | |
| Halozyme INC | $17.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.